A lab-made protein called JAM20 sticks tightly to all three versions of the mutated RAS protein found in cancer, whether the protein is in its 'on' or 'off' state, showing it can block multiple cancer-driving forms of RAS with one agent.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether pan-RAS binding agents consistently achieve higher clinical efficacy than isoform-specific inhibitors across RAS-mutant cancer subtypes.
A systematic review and meta-analysis of all published clinical trials comparing pan-RAS inhibitors (targeting Switch I/II or other conserved regions) with isoform-specific inhibitors (e.g., sotorasib) in patients with KRAS, HRAS, or NRAS-mutant cancers, measuring response rates and survival outcomes.
Whether a pan-RAS inhibitor targeting the Switch I/II pocket improves survival compared to an isoform-specific inhibitor in patients with diverse RAS mutations.
A double-blind RCT of 250 patients with advanced RAS-mutant cancers (KRAS, HRAS, NRAS), randomized to receive a Switch I/II-targeting biologic (e.g., JAM20 analog) versus a mutant-specific inhibitor (e.g., adagrasib), with progression-free survival as primary endpoint and RAS isoform as stratification factor.
Whether tumors with RAS mutations that preserve the Switch I/II pocket structure are more likely to respond to pan-RAS inhibitors.
A prospective cohort of 200 patients with RAS-mutant cancers undergoing treatment with a Switch I/II-targeting agent, with tumor sequencing and structural modeling to classify mutations by pocket accessibility, correlating with treatment response.
Whether patients whose tumors have RAS mutations with high Switch I/II pocket conservation are more likely to respond to pan-RAS inhibitors than those with mutations that disrupt the pocket.
A case-control study comparing 40 responders to a pan-RAS inhibitor with 80 non-responders, analyzing RAS mutation types and structural models of the Switch I/II pocket to determine if pocket conservation predicts response.
The frequency of RAS mutations that maintain an intact Switch I/II pocket across different cancer types.
A cross-sectional analysis of 500 tumor samples from pancreatic, lung, and colorectal cancers, using structural bioinformatics to determine the proportion of KRAS, HRAS, and NRAS mutations that preserve the Switch I/II pocket conformation.